## 2018 MDA Clinical Conference

Muscular Dystrophy Association • #MDAClinicCon • mda.org

## **Program Agenda**

<b>Sunday, March 11, 2018</b>
-------------------------------

4 – 6:30 p.m.	Registration	Regency Foyer
5 – 6 p.m.	Keynote Speaker	
6 – 8 p.m.	Champions Welcome Reception	Independence Center A
Monday, Marc	ch 12, 2018	
6 – 6:45 a.m.	MDA Team Momentum Fun Run/Muscle Walk	Lobby
7 – 7:50 a.m.	Breakfast	Independence Center B
7 – 7:50 a.m.	United States National Amyotrophic Lateral Sclerosis (ALS) Registry Breakfast	Potomac III IV V VI Toxic Substances and
8 – 8:30 a.m.	Opening Session	Regency CDEF
Session #1: What Session Chair: R	t's New Inabi Tawil	Regency CDEF
8:30 – 9 a.m.	Amyotrophic Lateral Sclerosis (ALS)  James D. Berry, M.D., M.P.H., Massachusetts General Hos	pital
9 – 9:30 a.m.	Duchenne Muscular Dystrophy (DMD)  Kathryn Wagner, M.D., Ph.D., Kennedy Krieger Institute	
9:30 – 10 a.m.	Facioscapulohumeral Muscular Dystrophy (FSHD)  Rabi Tawil, M.D., University of Rochester Medical Center	
10 – 10:30 a.m.	Coffee Break	Independence Center A
10:30 – 11 a.m.	Spinal Muscular Atrophy (SMA) Richard S. Finkel, M.D., Nemours Children's Hospital	

11 – 11:30 a.m.	Myotonic Dystrophy (DM) Charles Thornton, M.D., University of Rochester Medical Cen	ter
11:30 – 12 p.m.	Myasthenia Gravis (MG)  James F. Howard, Jr., M.D., FAAN, The University of North C	arolina at Chapel Hill
12 – 1:30 p.m.	Lunch	Independence Center B
Session #2: Adva Session Chair: I	ances in Personalized Medicine Eric Olson	Regency CDEF
1:30 – 2:10 p.m.	Correction of Duchenne Muscular Dystrophy by Genome Editing Eric Olson, Ph.D., UT Southwestern Medical Center	,
2:10 – 2:50 p.m.	Scaling Up Genomic Diagnosis of Muscle Disorders  Daniel MacArthur, Ph.D., Broad Institute of Harvard and MI	Г
2:50 – 3:30 p.m.	Advancing the Role of Digital Health in Neuromuscular Disease Murray Aitken, MBA, IQVIA Institute for Human Data Science	ce
3:30 – 4 p.m.	Coffee Break	Independence Center A
Session #3: MD	DA Flagship Initiatives	Regency CDEF
4 – 4:45 p.m.	MDA ONEvoice Kristin Stephenson, M.H.A., J.D., Muscular Dystrophy Asso	ociation
4:45 – 5:30 p.m.	MDA MOVR Registry Grace K. Pavlath, Ph.D., Muscular Dystrophy Association	
5:30 - 6 p.m.	Break	
6 – 8 p.m.	MDA Champions Networking Reception	Independence Center A

## Tuesday, March 13, 2018

7 – 8 a.m.	Breakfast	Independence Center B
Sessions #4, 5 a	and 6 are Concurrent Sessions	
	est Practices in Cardiac Care Elizabeth McNally	Regency EF
8 – 8:30 a.m.	Cardiac Management for the Muscular Elizabeth McNally, M.D., Ph.D., N Medicine	Dystrophy Lifespan orthwestern University, Feinberg School of
8:30 – 9 a.m.	Cardiac Screening, Surveillance and M Jennifer Strande, M.D., Ph.D., Me	Management in the Myotonic Dystrophy Patient edical College of Wisconsin
9 – 9:30 a.m.	Management of Neuromuscular-Assoc Pradeep P.A. Mammen, M.D., F.A	iated Cardiomyopathy A.C.C., FAH, UT Southwestern Medical Center
9:30 – 10 a.m.	Arrhythmia Monitoring and Arrhythmia Andreas Barth, M.D., Ph.D., John	Management in Muscular Dystrophies s Hopkins University, School of Medicine
	est Practices in Physical Therapy in SMA . <b>Jacqueline Montes</b>	Regency CD
8 – 8:30 a.m.		gement for Type 1 Spinal Muscular Atrophy (SMA) PCS, The Children's Hospital of Philadelphia
8:30 – 9 a.m.	Best Practices in Rehabilitation for Spi Onset SMA Leslie Nelson, P.T., UT Southwes	nal Muscular Atrophy (SMA) in Patients with Later tern Medical Center
9 – 9:30 a.m.		ngement for Adult Spinal Muscular Atrophy (SMA)  T., Columbia University Medical Center
9:30 – 10 a.m.	Exercise in Spinal Muscular Atrophy Jacqueline Montes, P.T., Ed.D., I	ICS, Columbia University Medical Center
	est Practices in Bone Health	Washington Room
8 – 8:30 a.m.	Partnering for Better Bone Health Outco Mathula Thangarajh, M.D., Children	
8:30 – 9 a.m.	Partnering for Better Bone Health Outco Susan D. Apkon, M.D., Seattle Chile	
9 – 9:30 a.m.	Bone Health: PM&R View Dennis Matthews, M.D., Children's	Hospital Colorado

9:30 – 10 a.m. Clinical Management in Bone Health: Current Approach and Future Directions  Alison Boyce, M.D., National Institutes of Health				
10 – 10:30 a.m.	Coffee BreakIndependence Center A			
Sessions #7 and	8 are Concurrent Sessions			
Session #7: Bes Session Chair: L	t Practices in Technology in Health CareRegency EF aura Hagerty			
10:30 – 11 a.m.	Accelerating Discovery in Neurological Disorders with Cognitive Computing Elenee Argentinis, J.D., Watson Health Life Sciences Solutions			
11 – 11:30 a.m.	Telemedicine in Health Care  James D. Berry, M.D., M.P.H., Massachusetts General Hospital			
11:30 – 12 p.m.	Answer ALS  Jeffrey D. Rothstein, M.D., Ph.D., Johns Hopkins University, School of Medicine			
Session #8: Bes Session Chair: B	t Practices in Dysphagia/NutritionRegency CD ecky Hurst-Davis			
10:30 – 11 a.m.	Nutrition in Neuromuscular Disease  Becky Hurst-Davis, M.S., RD, CSP, CD, CNSC, University of Utah, School of Medicine			
11 – 11:30 a.m.	Dysphagia in Neuromuscular Disease  Kiera Berggren, SLP, University of Utah, School of Medicine			
11:30 – 12 p.m.	Nutritional Considerations in Neuromuscular Disease  Elizabeth Miller, M.S., RD, Shriner's Hospital for Children, Salt Lake City			
12 – 1:30 p.m.	LunchIndependence Center B			
Sessions #9, 10 a	and 11 are Concurrent Sessions			
Session #9: New Session Chair: R	vborn ScreeningRegency EF			
1:30 – 2:15 p.m.	Newborn Screening  R. Rodney Howell, M.D., Miller School of Medicine, University of Miami			
2:15 – 3 p.m.	Panel Discussion  Panelists:  Rebecca Abbott, March of Dimes Peter Kyriacopoulos, Association of Public Health Laboratories Paul Melmeyer, National Organization for Rare Disorders Mike Watson, Ph.D., FACMG, ACMG, Foundation for Genetic & Genomic Medicine			
3 – 3:30 p.m.	Coffee BreakIndependence Center A			
3:30 – 4 p.m.	Robert Griggs, M.D., FAAN, University of Rochester Medical Center			

4 – 4:30 p.m. 4:30 – 5 p.m.	Barry Byrne, M.D., University of Florida Kathryn Swoboda, M.D., Massachusetts General Hospital
	gmentative Communication (Workshop)Washington Room
1:30 – 3 p.m.	ALS and AAC and Early Engagement in Assessment, System Design and Implementation John M. Costello, M.A., CCC-SLP, Boston Children's Hospital
Session #11: Pe Session Chair: I	diatric/Adult Transition (Panel Discussion)Regency CE  Diane V. Murrell
1:30 – 3 p.m.	Transition from Pediatric to Adult-Based Health Care for Youth with Neuromuscular Disease
	Panelists:  Lauren Elman, M.D., University of Pennsylvania Medical Center  Diane V. Murrell, M.S.W., LCSW, Texas Children's Hospital  Sarah Stoney, M.S.W., LSW, The Children's Hospital of Philadelphia
3 – 3:30 p.m.	Coffee Break
Sessions #9, 12	and 13 are Concurrent Sessions
	espiratory HealthRegency CE  John Hansen-Flaschen and Venessa Holland
3:30 – 4 p.m.	Home Assisted Ventilation  John Hansen-Flaschen, M.D, University of Pennsylvania, School of Medicine
4 – 4:30 p.m.	Transitions to Home Mechanical Ventilation Craig Dale, R.N., Ph.D., University of Toronto
4:30 – 5 p.m.	Respiratory Management of the Neuromuscular Patient with Airway Clearance Devices and Lung Volume Recruitment  Venessa Holland, M.D., M.P.H., Houston Methodist Neurological Institute
Session #13 Ca Session Chair: I	ure Coordination (Panel Discussion)Washington Room Mona Shahbazi
3:30 – 5 p.m.	Best Practices in Care Coordination
	Panelists:  Rebecca Axline, LCSW-S, Houston Methodist Neurological Institute Susan Nease, DNP, ANP, Medical University of South Carolina Mona Shahbazi, N.P., M.S.N., Hospital for Special Surgery
5 – 5:30 p.m.	Break
5:30 – 8 p.m.	Poster Session and ReceptionIndependence Center A

## Wednesday, March 14, 2018

7 – 8 a.m.	Breakfast	Independence Center E
	linical Trials	Regency CDEF
8 – 8:30 a.m.	Suppressing Neuroinflammation: ALS Therapy Comes of Age Stanley H. Appel, M.D., Houston Methodist Neurological Ins	stitute
8:30 – 8:50 a.m.	AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in Event-Free Survival and Achievement of Developmental Milesto Doug Sproule, M.D., AveXis, Inc.	
8:50 – 9:10 a.m.	Correlations between MRI and Functional Measurements in DM. the Phase 2 Domagrozumab Study Sarah Sherlock, Ph.D., Pfizer	D Boys: Baseline data from
9:10 – 9:30 a.m.	Updated Results from ATB200-02: a First-in-Human, Open-Labe ATB200 Co-Administered with AT2221 in Adults with Pompe Dis <b>Tahseen Mozaffar, M.D.</b> , University of California, Irvine	•
9:30 – 10 a.m.	Nusinersen in Infants Who Initiate Treatment in a Presymptomat Efficacy and Safety Results from the Phase 2 NURTURE Study Darryl De Vivo, M.D., Columbia University Medical Center	
10 – 10:30 a.m.	Coffee Break	Regency Foye
10:30 – 10:50 a.m	m. Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dy Patients with Genetic Mutations Amenable to Exon 53 Skipping Elizabeth Smyth, FNP-BC, Sarepta Therapeutics, Inc.	
10:50 – 11:10 a.m	m. CALLISTO: A Phase 1 Open-Label, Sequential Group, Cohort and Safety of Omigapil in LAMA2 and COL6-Related Dystrophy A Reghan Foley, M.D., NINDS, NIH	
11:10 – 11:30 a.m	m. Biomarkers for Muscular Diseases – Data Supporting Glutamat as a Specific Biomarker of Liver Damage Jane Larkindale, Ph.D., Critical Path Institute/FARA	te Dehydrogenase (GLDH)
11:30 – 11:50 a.m	m. A Phase 2 Study of AMO-02 (tideglusib) in Congenital and Chil Dystrophy Type 1 Joseph Horrigan, M.D., AMO Pharma Ltd.	dhood Onset Myotonic